Windtree Therapeutics Inc /De/
Windtree Therapeutics is a U.S.-based biotechnology company focused on developing therapies for cardiovascular disease, hypertension, and oncology. Its portfolio includes istaroxime, rostafuroxin, preclinical SERCA2a activators, and an aPKCi inhibitor, alongside licensing arrangements and product-candidate partnerships.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueTherapies aimed at acute heart failure, cardiogenic shock, and related cardiovascular conditions.
Genetically targeted treatment programs for specific hypertension patient populations.
Early-stage inhibitor programs being explored for rare and broad oncology indications.
Out-licensed programs and partnership arrangements that can generate non-product revenue.
Customers
Windtree’s direct customers are primarily pharmaceutical and biotechnology partners, licensees, and potential acquirers of its development assets rather than a broad consumer base. In a commercialization model, its therapies would ultimately be used by hospitals, physicians, and specialty care providers treating acute cardiovascular disease or oncology patients. The company also seeks partners in specific geographic markets to support development, licensing, and product collaboration.
License or collaborate on drug candidates and development programs to share risk and advance assets.
Companies or assets with FDA-approved products that can be acquired to build revenue-generating subsidiaries.
Hospitals and physicians that would use approved cardiovascular therapies in acute care settings.
Patients with genetically defined hypertension or oncology indications targeted by specific programs.
Strategy
Windtree’s strategy is to advance its cardiovascular and oncology pipeline while building a revenue-generating platform through acquisitions of small companies with FDA-approved products. It also seeks licensing, alliances, and product collaborations to secure capital and broaden commercialization pathways. This approach combines internal development with external asset acquisition to create future operating subsidiaries.
Clinical progress is needed to create value in the core development portfolio.
FDA-approved products can provide commercial revenue while the pipeline matures.
Collaborations can provide funding, market access, and development support.
Geography
Windtree is headquartered in the United States and operates as a U.S.-based development-stage biotech company. Its disclosures reference potential licensing arrangements and drug product collaborations focused on specified geographic markets, but no country-level revenue breakdown is disclosed in the provided materials. The business is therefore geographically shaped more by partner selection, regulatory pathways, and trial/commercialization locations than by a broad manufacturing footprint.
Risks
Windtree faces the typical risks of a development-stage biotech company: clinical failure, regulatory setbacks, and uncertainty around commercialization. The company also has specific financing, listing, and asset-valuation risks tied to its capital structure, intangible assets, and dependence on external funding and strategic transactions.
- Going concern and near-term funding riskImpact: CriticalLikelihood: High
The company needs additional capital to finance operations and development activities.
Exposure: Corporate liquidity and continuity of R&D
- Nasdaq listing compliance riskImpact: HighLikelihood: High
Failure to meet continued listing requirements can lead to delisting.
Exposure: Common stock trading and capital access
- Clinical and regulatory development riskImpact: High
Drug candidates may fail in trials or not obtain required approvals.
Exposure - Intangible asset impairment riskImpact: High
IPR&D values depend on future commercial success and development assumptions.
Exposure: Istaroxime and rostafuroxin intangible assets
Accounting
Judgemental itemsValuation depends on future development success, timing, and discount rates.
Impact: Can create material impairment charges if prospects weaken
Convertible and preferred instruments may require complex valuation inputs.
Impact: Can affect reported earnings and equity balances
Redemption features require periodic accretion to redemption value.
Impact: Reduces earnings available to common shareholders
Management must evaluate whether funding is sufficient for 12 months.
Impact: Influences disclosure and investor assessment of solvency risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
OS Therapies Inc
OSTX · Pharmaceutical Preparations
OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates.
Werewolf Therapeutics, Inc.
HOWL · Pharmaceutical Preparations
Tempest Therapeutics, Inc.
TPST · Pharmaceutical Preparations
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Last updated: 24/09/2026